SCHEMBL30980762

SCHEMBL30980762

CC(CCCNC(=O)OC(C)(C)C)(CCCNC(=O)OC(C)(C)C)NC(=O)NCCOCCOCCOCCNC(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
IDO1 P14902 1/20 0.51
MAPT P10636 3/20 0.48
HTT P42858 1/20 0.47
SYK P43405 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.45
TGM2 P21980 1/20 0.43
BCHE P06276 1/20 0.43
CNR2 P34972 1/20 0.43
KEAP1 Q14145 3/20 0.43
NFE2L2 Q16236 3/20 0.43
KLK7 P49862 2/20 0.42
KLK5 Q9Y337 2/20 0.42
POLB P06746 1/20 0.41
MAPK1 P28482 1/20 0.41
FOLH1 Q04609 1/20 0.40
MEN1 O00255 1/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980695 0.88 LMNA (0.60) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL12196470 0.87 SMN1; SMN2 (0.76) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL15738439 0.86 LMNA (0.71) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL20825713 0.86 LMNA (0.71) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL20288399 0.83 LMNA (0.59) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL30980602 0.82 LMNA (0.48) LMNASMN1; SMN2MAPTHTTL3MBTL1
SCHEMBL15746977 0.81 LMNA (0.70) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL24383295 0.81 LMNA (0.63) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL13480435 0.81 MAPT (0.65) LMNASMN1; SMN2IDO1MAPTHTT
SCHEMBL13938297 0.81 HTT (0.65) LMNASMN1; SMN2IDO1MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 WO disclosed